ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for charts Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.

CRIS Curis Inc

14.47
-0.05 (-0.34%)
26 Abr 2024 - Cerrado
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Curis Inc CRIS NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
-0.05 -0.34% 14.47 23:00:04
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
14.44 14.25 14.6899 14.47 14.52
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
05/4/202406:30PRNUSCuris Reports Inducement Grants Under NASDAQ Listing Rule..
04/4/202406:30PRNUSCuris to Present at Upcoming Healthcare Conferences in April
12/2/202415:16EDGAR2Form SC 13G - Statement of acquisition of beneficial..
08/2/202415:36EDGAR2Form S-8 - Securities to be offered to employees in employee..
08/2/202415:27EDGAR2Form S-3 - Registration statement under Securities Act of..
08/2/202415:01EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
08/2/202407:01EDGAR2Form 8-K - Current report
08/2/202407:00PRNUSCuris Provides Fourth Quarter 2023 Business Update
01/2/202407:00PRNUSCuris to Release Fourth Quarter 2023 Financial Results and..
11/1/202407:13EDGAR2Form 8-K - Current report
05/1/202407:00PRNUSCuris Reports Inducement Grants Under NASDAQ Listing Rule..
21/12/202315:00EDGAR2Form 10-K/A - Annual report [Section 13 and 15(d), not S-K..
12/12/202307:00PRNUSCuris Announces Initial Combination Study Data from its..
11/12/202307:00PRNUSCuris Presented Clinical Data from the TakeAim Leukemia..
06/12/202307:00PRNUSCuris Announces Three Presentations at ASH
05/12/202307:00PRNUSCuris Enters into Agreement for Emavusertib / Pembrolizumab..
02/11/202307:03EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
02/11/202307:01EDGAR2Form 8-K - Current report
02/11/202307:00PRNUSCuris Provides Third Quarter 2023 Business Update
26/10/202307:30PRNUSCuris to Release Third Quarter 2023 Financial Results and..
06/10/202307:56PRNUSCuris Reports Inducement Grants Under NASDAQ Listing Rule..
28/9/202315:05EDGAR2Form 8-K/A - Current report: [Amend]
28/9/202307:54EDGAR2Form 8-K - Current report
12/9/202307:00PRNUSCuris Announces Date for the 2nd Symposium on IRAK4 in..
06/9/202307:13PRNUSCuris to Present at Upcoming Healthcare Conferences in..
18/8/202315:02EDGAR2Form DEF 14A - Other definitive proxy statements
04/8/202315:09EDGAR2Form PRE 14A - Other preliminary proxy statements
03/8/202315:04EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
03/8/202315:02EDGAR2Form 8-K - Current report
03/8/202315:01PRNUSCuris Provides Second Quarter 2023 Business Update
27/7/202317:25PRNUSCuris to Release Second Quarter 2023 Financial Results and..
06/7/202315:30EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
06/7/202308:28EDGAR2Form 8-K - Current report
06/7/202307:04EDGAR2Form 8-K - Current report
06/7/202307:01PRNUSFDA Removes Partial Clinical Hold on TakeAim Leukemia Study..
06/7/202307:00PRNUSCuris Announces $15.1 Million Registered Direct Offering
05/5/202306:30PRNUSCuris Reports Inducement Grants Under NASDAQ Listing Rule..
04/5/202315:01PRNUSCuris Provides First Quarter 2023 Business Update

Su Consulta Reciente

Delayed Upgrade Clock